<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1540" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="922" end="925"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="960" end="970"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1011" end="1022"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: This prospective phase II study assessed the efficacy and safety of&#13;&#10;bevacizumab plus chemotherapy regimens commonly used in the second-line treatment&#13;&#10;of metastatic colorectal cancer (mCRC).&#13;&#10;METHODS: Patients with mCRC who progressed or relapsed after first-line&#13;&#10;oxaliplatin-based or irinotecan-based treatment received bevacizumab 2.5&#13;&#10;mg/kg/week plus chemotherapy until disease progression. The primary endpoint was &#13;&#10;disease-control rate (DCR). Secondary endpoints included progression-free&#13;&#10;survival (PFS), overall survival (OS), objective response rate (ORR), and safety.&#13;&#10;RESULTS: Fifty-three patients (66% men; median age, 62 years old) received&#13;&#10;second-line bevacizumab plus folinic acid, fluorouracil, and irinotecan (FOLFIRI;&#13;&#10;57%), folinic acid, fluorouracil, oxaliplatin (FOLFOX; 26%), irinotecan (15%), or&#13;&#10;capecitabine plus irinotecan (XELIRI; 2%). The DCR was 87% (95% CI, 77%-97%); ORR&#13;&#10;was 32% (95% CI, 19%-46%). Median PFS was 6.5 months (95% CI, 5.8-7.8 months) and&#13;&#10;median OS 19.3 months, (95% CI, 14.2-25.1 months).The most frequent grade 3/4&#13;&#10;adverse events included neutropenia (21%), diarrhea (15%), asthenia, and vomiting&#13;&#10;(9% each). Five patients (9%) had grade 3/4 targeted toxicities: grade 3&#13;&#10;hypertension (n = 2), grade 3 venous thromboembolism (n = 2), and grade 4&#13;&#10;arterial thromboembolism (n = 1). None of these events led to death during the&#13;&#10;study.&#13;&#10;CONCLUSION: Bevacizumab plus standard second-line chemotherapy is highly active&#13;&#10;in patients with mCRC and has an acceptable safety profile."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
